Glibenclamide treatment recruits beta-cell subpopulation into elevated and sustained basal insulin synthetic activity.


Use of sulfonylureas in diabetes treatment is based on their insulin-releasing effect on pancreatic beta-cells. Prolonged action is known to degranulate beta-cells, but functional consequences have not been examined at the cellular level. This study investigates influences of in vivo (48-h) and in vitro (24-h) glibenclamide treatment on the functional state… (More)


  • Presentations referencing similar topics